University of Calgary Cumming School of Medicine

CURRICULUM VITAE

I. BIOGRAPHICAL DATA

Name: Gloria Beatriz Roldán Urgoiti

Address: Department of Medical Oncology

Tom Baker Cancer Centre

1331 29 St NW Calgary, Alberta

T2N 4N2

Telephone: 403-521-3446

E-mail gloria.roldanurgoiti@albertahealthservices.ca

Present Rank: Clinical Associate Professor

Department: Departments of Medicine and Oncology

Faculty: Faculty of Medicine Institution: University of Calgary

II. ACADEMIC RECORD

Final Degree: MD

Date completed: July 31, 1999

Specialty: General Medicine (Family Medicine equivalent)
Institution: University of the Republic, Montevideo, Uruguay

Final Degree: Specialist in Medical Oncology

Date completed: June 15, 2004 Specialty: Medical Oncology

Institution: University of the Republic, Montevideo, Uruguay

Final Degree: MSc

Date completed: August 22, 2005 Specialty: Biomedical Research

Institution: Postgraduate Program in Medical Sciences (PROINBIO), Faculty of Medicine,

University of the Republic, Uruguay

Final Degree: Neuro-Oncologist
Date completed: June 30, 2011
Specialty: Neuro-Oncology

Institution: University of Calgary, Alberta, Canada

Final Degree: Licentiate of the Medical Council of Canada

Date completed: December 14, 2012

Institution: Medical Council of Canada

Final Degree: FRCPC

Date completed: June 30, 2014 Specialty: Internal Medicine

Institution: University of Calgary, Canada

Final Degree: FRCPC
Date completed: Sep 27, 2016
Specialty: Medical Oncology

Institution: University of Calgary, Canada

i. Undergraduate

1988-1990 University of the Republic, Uruguay, Residency in Medical Oncology, Montevideo,

Uruguay

1991-1999 Faculty of Medicine, University of the Republic, Uruguay

ii. Graduate and post-doctoral

2000-2004	University of the Republic, Uruguay, Residency in Medical Oncology, Montevideo, Uruguay
2003-2005	MSc (Honours), Thesis: Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer - Postgraduate Program in Medical Sciences (PROINBIO), Faculty of Medicine, University of the Republic, Uruguay
2005-2007	University of Calgary, Fellowship in Clinical Neuro-Oncology, Canada
2007/10-11	Memorial Sloan Kettering Cancer Centre, Observership at Neuro-Oncology Unit, New York, US
2007-2008	University of Calgary, Hotchkiss Brain Institute, Fellowship in Brain Research, Canada
2009-2011	University of Calgary, Fellowship in Neuro-Oncology & Translational Research
2010-2016	University of Calgary, Adjunct Research Assistant Professor
2011-2014	University of Calgary, Residency in Internal Medicine
2014-2016	University of Calgary, Fellow in Medical Oncology
2016-present	University of Calgary, Clinical Assistant Professor

iii. Licensure, Certification, and Boards

2016-present General Register in Internal Medicine, College of Physicians & Surgeons of Alberta,

entitled to practice within facilities under the jurisdiction of the University of Calgary,

#19267

2016 Educational registration, College of Physicians & Surgeons of British Columbia

2016 Royal College of Physicians and Surgeons of Canada Certification (FRCPC) Medical

Oncology

- 2005-2016 Educational/Courtesy registration, College of Physicians & Surgeons of Alberta, entitled to practice within facilities under the jurisdiction of the University of Calgary, #19267
- 2015 Royal College of Physicians and Surgeons of Canada Certification (FRCPC) Internal

Medicine

2013 Educational registration, College of Physicians & Surgeons of British Columbia

III. AWARDS AND DISTINCTIONS

- 2023 2028 Friedenreich CM, Yang L (co-PI), Benham J, Brenner DR, Culos-Reed N, Courneya KS, Kopciuk KA, McNeely M, Vallance J (co-investigators), Matthews CE, Lupichuk S, Roldan Urgoiti G, Mackey J (collaborators). Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Understanding how physical activity, sedentary behaviour and health-related fitness are related to breast cancer survival. CIHR Project Grant \$1,151,326.
- Alberta Cellular Therapy and Immune Oncology Initiative (ACTION). AB Children's Hospital Foundation CAD 3,176,472 over 5 years; ExCELLerate Canada CFI funding CAD 5,187,685 (not exclusive for Calgary)
- 2020 Investigator Initiated Grant TBCC 2020 CAD 170,805: Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma. De Robles P, Kelly J, Luchman A, Weiss S, Roldan Urgoiti G, Tsang R, Folkman F, Cairncross G.
- 2018 CIHR Operating Grant: Epigenetics Clinical Translation program 2018. CAD 842,000 (Awarded: March 2019 for 4 years) "MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics." Morris D, Bonni S, Joy A, Nixon N, Roldan Urgoiti G, Zhang Q.
- 2018 Clinical Preceptor Education Award 2018 Pfizer Selected by Residents in Medical Oncology.
- Carole May Yates Memorial Endowment for Cancer Research award. CAD 18,900. Evaluation of temozolomide synergy with existing treatments for premenopausal triple negative breast cancer harboring MGMT promoter methylation. Morris D, **Roldan Urgoiti G**, Kornaga E, Chan A, Yang A
- 2017 CIHR Cancer Progression & Therapeutics Grant 2017 CAD 1,243,125

 Mobilizing anti-tumor microglia/macrophages with niacin to improve the prognosis of glioblastoma: Bench to clinical trial and back. Yong, VW, de Robles, P, Dunn J, Kelly J, Roldán Urgoiti G
- 2017 Hotchkiss Brain Institute Translational Grant CAD 200,000

 Mobilizing anti-tumor microglia/macrophages with niacin to improve the prognosis of glioblastoma: Bench to clinical trial and back. Yong, VW, de Robler, P, Dunn J, Kelly J, Roldán Urgoiti G
- 2016 2nd place award abstract Canadian Association of Medical Oncologist 2016 Meeting. **Roldán Urgoiti G.**, Ibnshamsah F, Yang H, Lupichuk S. Impact of routine subspecialty pathology review on the care of women age </= 65 years with lymph node negative breast cancer: a practice review. April 28 2016, Toronto, ON
- 2014 Best Oral Presentation. Internal Medicine Residency Program Resident Research Day 2014. **Roldán Urgoiti G.**, Gustafson K, Klimowicz A, Petrillo S, Magliocco A, Doll C. Prognostic Value

Of HPV Status And P16 Expression In Patients With Carcinoma Of The Anal Canal. April 24/2014, University of Calgary, Alberta

Junior Oncology Award in recognition of overall achievements, 5th Winter Oncology

Conference, Montevideo, Uruguay

2012 Jeremy Jass Prize for Research Excellence in Pathology.

Yip S, Butterfield Y, Morozova O, Chittaranjan S,Blough M, An J, Birol I, Chesnelong C, Chiu R,

Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis D,

Maslova A, Moore R, Moradian A, Mungall K, Perizzolo M, Qian J, **Roldán Urgoiti G.**, Smith E, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall A, Jones S, Morin G, Chan J, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and

1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226: 7–16

2008 Canadian Brain Tumor Consortium, Young Investigator in Clinical Research Award, CAD 3,000.

This was an educational grant in recognition of Clinical Research presented during the 13th Biennial Canadian Neuro-Oncology Meeting 2008. I had 6 posters and 4 oral presentations in

this Conference

IV. ACADEMIC APPOINTMENTS

2020- present University of Calgary, Clinical Associate Professor

2016-2020 University of Calgary, Clinical Assistant Professor

2010-2016 University of Calgary, Adjunct Research Assistant Professor

V. EDUCATIONAL ACTIVITIES

i. Undergraduate Education

2024/03 MMI (mini interviews) assessor for admission to the Cumming School of Medicine.

2019/03 MMI (mini interviews) assessor for admission to the Cumming School of Medicine.

2017/10 Awareness in UME teaching re: Cultural Differences in Breast Health

2016/07-ongoing Supervision of clinical clerks rotating through Medical Oncology

2016/12 Undergraduate Medical Education – Breast Cancer

2016/07 Undergraduate Medical Education Week-0 Professionalism facilitator

2016/01 Medical Student Engagement in Research Seminar – Undergraduate Medical Education

Office, Cumming School of Medicine (1 hour)

2016/01 Participated in Mock Specialty Interviews for UME organized by Alberta Medical

Association and Canadian Medical Association (4 hours)

2015/10	Decimal a nilat course of "Introduction to Decemb" for undergraduate students. Decuest
	Designed a pilot course of "Introduction to Research" for undergraduate students. Request
	for assistance in this area was sent by UME education on October 2015. In summary it
	would imply four 1-hour sessions in a small group setting where students will need go from
	design to publishing a prototype of two research types usually developed during residency.
	i.e. a chart review and a case report. Currently under review by the Undergraduate Medical

Education Office

2015/09 Undergraduate education Week-0 Professionalism facilitator

2008/11 Communication Skills – Small Group Preceptor, Undergraduate Program, Cumming School

of Medicine, Calgary, AB

ii. Graduate

2023/03/13	PhD External Examiner – Ms Laura Mah – PhD student Dr. Douglas Mahoney Lab – CAR-T cell therapy.
2020/11-2022	PhD Supervisory Committee member – Ms. Julia Daun - Implementing Exercise in the Clinical Care Pathway in Neuro-Oncology PhD proposal (Health and Wellness Lab; Faculty of Kinesiology)
2018/09- 2019/ 04	Masters Committee – Ms. Alice Yuan (Dr. G. Cairncross' lab; Arnie Charbonneau Cancer Institute)
2018/05 -2019	Masters Committee – Ms. Elizabeth Bering (Dr. G. Cairncross' lab; Arnie Charbonneau Cancer Institute)
2017/02-2021	Masters Committee – Ms. Alice Yuan (Dr. G. Cairncross' lab: Arnie Charbonneau

iii. Postgraduate (Lectures, Research and Clinical Fellows)

Cancer Institute)

2023/04	Judge Poster Presentation Hotchkiss Brain Institute Research Day
2023/04	Virtual Professionalism Workshop in AIMG Externship Orientation, PGME, Calgary, AB
2022/05	Judge Poster Presentation Hotchkiss Brain Institute Research Day
2022/04	Virtual Professionalism Workshop in AIMG Externship Orientation, PGME, Calgary AB
2021/06	Judge in the Department of Oncology Residents Research Day
2021/01	Neuro-Oncology for the Medical Oncologist – Medical Oncology Academic Half Day
2021/05	Virtual Professionalism Workshop in AIMG Externship Orientation, PGME, Calgary, AB
2020/10	MCCQE Part II examiner training (exam cancelled due to COVID-19) for the Medical Council of Canada.
2020/06	Virtual Professionalism Workshop in AIMG Externship Orientation, PGME, Calgary, AB
2020/05	Judge Poster Presentation Hotchkiss Brain Institute Research Day.

2020/05	Virtual Professionalism presentation for Orientation for Internationally Trained Physicians starting Fellowships, PGME, Cumming School of Medicine.
2019/10	MCCQE Part II examiner October 26 and 27/2019 for the Medical Council of Canada.
2019/07	Professionalism workshop in Orientation for Internationally Trained Physicians starting Fellowships, PGME, Cumming School of Medicine.
2019/06	Judge in the Department of Oncology Residents Research Day
2019/05	Judge Poster Presentation Hotchkiss Brain Institute Research Day.
2019/04	Professionalism Workshop in AIMG Externship Orientation, AIMG, Calgary, AB
2018/10	Internal Medicine Interest Group "Speed Dating" - Career Development Event; University of Calgary
2018/08	Treatment of Anal Canal Carcinoma – Medical Oncology Academic Half Day
2018/06	Neuro-Oncology for the Medical Oncologist – Medical Oncology Academic Half Day
2018/06	Judge in the Department of Oncology Residents Research Day
2018/05	Dealing with professionalism challenges - International Institute of Medical Education Leadership, May 28-June 8/2018
2018/05	Judge in the Hotchkiss Brain Institute Research Day poster session
2018/04	Medical Professionalism Workshop for AIMGs matched to residency in AB, Cumming School of Medicine, Office of Professionalism, Equity and Diversity
2017/09	Journal Club - CREATE-X Trial - (Supervised Dr. Osama Ahmed)
2017/07	Professionalism Workshop for AIMG Fellows, AIMG, Cummings School of Medicine
2017/07	Supervision of postgraduates rotating through Medical Oncology
2017/06	Judge in the Department of Oncology Residents Research Day
2017/04	Medical Professionalism Workshop for AIMGs matched to residency in AB, Cumming School of Medicine, Office of Equity and Professionalism
2017/03	Supervisor: Population Based Analysis of Male Breast Cancer in Alberta – PGY4, Medical Oncology: Dr. Osama Ahmed
2017/03	Supervisor: Protracted Pseudoprogression in Patients with Newly Diagnosed Glioblastoma. A population based analysis. Neuro-Oncology Fellow: Dr. Wajid Sayeed
2017/02	Triple Negative Breast Cancer – Medical Oncology Academic Half Day, Univ. of Calgary
2017/01	Design of MOCK Medical Oncology exam for Med Onc Fellows. Univ. of Calgary
2016/08	Neuro-Oncology for the Medical Oncologist – Medical Oncology Academic Half Day
2016/07	Workplace teaching - It is part of daily activities to orientate, teach and give constructive feedback to residents and clerks that rotate through the tumor groups I am working with.

2015/08	Alberta IMG practice OSCE examiner, IMG program, Cumming School of Medicine, Calgary, Alberta
2015/07	Adverse events of most frequent chemotherapy agents - Medical Teaching Unit Oncology Lecture, Department of Internal Medicine, University of Calgary, Alberta
2015/02	Oncologic Emergencies - Medical Teaching Unit Oncology Lecture, Department of Internal Medicine, University of Calgary, Alberta
2015/01	Bone Health in Cancer Patients – Medical Oncology Noon Rounds, Department of Oncology, Calgary, Alberta
2014/12	Medical Teaching Unit Oncology Lecture – Colorectal Cancer, Department of Internal Medicine, University of Calgary, Alberta
2014/08	Alberta IMG practice OSCE examiner, IMG program, Calgary, Alberta
2011-2016	Mentorship meetings (quarterly) with Internal Medicine Residents and Dr. Maria Bacchus

iv. Continuing Medical Education

2019/10	Hormonal Receptor Positive Breast Cancer Update. Community Oncology Tumour Team Update Meeting, Edmonton, AB.
2019/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 13/2019. University of Calgary and University of Alberta. Oral presentation on General Practitioner in Oncology Focused Training Program.
2018/10	Community Oncology Tumour Team Update Meeting. HER2 positive and triple negative breast cancer (87 participants), Edmonton, AB.
2018/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 14/2018. University of Calgary and University of Alberta. Oral presentation on Cultural Differences in Breast health
2018/05	Cultural Differences in Breast Health – Promotion through media and discussion with Family Medicine Program members to improve awareness at PGME and UME levels
2017/05-11	Leadership Mentorship Sessions - OLDO coaching - Dr. Craighead
2017/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 22, 2017. University of Calgary and University of Alberta. Oral presentation on Immunotherapy.
2016/02	Proposal of a standardized, uniform educational repository of presentations of topics in Medical Oncology for the Medical Teaching Unit; presented to PGME committee.

iv. Community Education

2015/09 Living Book – With the support of AHS Media and PR, 2008 participated in this public awareness event with the "book": "Treating patients with cancer. Measuring success with statistics and hugs."

VI. ADMINISTRATIVE RESPONSIBILITIES

i. Departmental

2022/04	TBCC Investigator Initiated Trial Grants Reviewer 2022
2022/02	Data Safety Monitoring Board (DSMB) for Dr. Monzon's Investigator Initiated Trial (MK-3475-418)
2021/05	TBCC Investigator Initiated Trial Grants Reviewer 2021
2020/10	TBCC Investigator Initiated Trial Grants Reviewer 2020
2020/08	Clinical Practice Guidelines Reviewer: Dexamethasone in gliomas – Alberta Health Services
2018/08-	General Practitioner in Oncology Focused Training Program - Program Director
2018/07-	Competency By Design (CBD) – Faculty advisor
2018/04-	Department on Oncology Search and Selection Committee
2018/02	TBCC Investigator Initiated Trial Grants Reviewer 2018
2017/09	Interview Radiotherapists for Locum position, Department of Oncology
2017/07	Clinical Practice Guidelines Reviewer: Oligometastases – CNS-013 version 1 – Alberta Health Services
2017/04-2021	Provincial Cancer Care Clinical Ethics Committee, member.
2017/03	AHS Hazardous Medication List and personal Protective Equipment (PPE) Guidelines reviewer.
2016/12	Clinical Practice Guidelines Reviewer: Low grade gliomas – CNS-003 version 4 – Alberta Health Services
2016/09	Clinical Practice Guidelines Reviewer: Malignant Biliary Obstruction – GI-012 Version 1 – Alberta Health Services.
2008/08	Clinical Practice Guidelines Reviewer – Low Grade Astrocytomas and Oligodendrogliomas CNS-003 version 1 – Alberta Health Services
2008/04	Clinical Practice Guidelines Reviewer – Anaplastic Astrocytomas and Oligodendrogliomas CNS-002 version 1. Alberta Health Services
2008/04	Clinical Practice Guidelines Reviewer – Glioblastoma CNS-001 version 1. Alberta Health Services
ii. Faculty	
2017/12	Interviews Candidates for Director Hotchkiss Brain Institute – representing Dept. Oncology
2017/07	Review of the Charbonneau Institute Strategic Plan (07/28/2017 retreat)

iii Hospital

2017-present Member, Southern Alberta CNS Tumour Group

2017-2020 Member, Southern Alberta Gastrointestinal Tumour Group

2017-present Member, Southern Alberta Breast Tumour Group

VII. PROFESSIONAL ACTIVITIES

i. Membership in Professional and Learned Societies

2023- Riddell Centre for Cancer Immunotherapy: Clinical Research and Discovery-Innovation

working groups

2022-2023 Steering Committee, Alberta Cellular Therapy and Immune Oncology (ACTION)

2018- present Arnie Charbonneau Cancer Institute Full Member

2018- present Alberta Breast Cancer Screening Program

2018- present CHECS – Creating Health Equity in Cancer Screening

2017 ACORN – Alberta Cancer Outcomes Research Network

2015-present Royal College of Physicians and Surgeons of Canada

2014-2016 Canadian Society of Internal Medicine; Resident Associate

2009-present Hotchkiss Brain Institute, Associate Member

2008–present Canadian Brain Tumor Consortium, Associate Member

2008-2009 Society of Clinical Research Associate Member

2006-present Society for Neuro-Oncology, Active Member

2006-2020 American Society of Clinical Oncology, Associate Member

2005-present Clark H Smith Brain Tumour Center, Member

2005-2015 Cooperative Uruguayan Oncologic Group (GOCUR), Founder Member

2000-2015 Society of Medical & Pediatric Oncology of Uruguay (SOMPU), Member

ii Professional Service

Grant Panels/Reviews

2019/09 Reviewer for Clark Smith Brain Institute Graduate Studentship 2019, University of

Calgary.

2019/09	Reviewer 2019 Postdoctoral Scholarship Funding Opportunity, Charbonneau Cancer Institute, University of Calgary.
2019/09	Reviewer for Clark Smith Brain Institute Graduate Studentship 2019, University of Calgary.
2019/09	Reviewer 2019 Postdoctoral Scholarship Funding Opportunity, Charbonneau Cancer Institute, University of Calgary.

Reviews for Journals and Medical Societies

2018	Canadian Journal of Neurological Sciences
2017/04	Review: Oncology Education Online Neuro-Oncology educational summary
2015	Canadian Journal of Neurological Sciences

Regional Committees

2023-	Riddell Centre for Cancer Immunotherapy Discovery and Innovation Working Group
2023-	Riddell Centre for Cancer Immunotherapy Clinical Research Working Group
2022/09	Interview of candidates for fellowship in Medical Oncology, Department of Oncology, University of Calgary, Alberta, Canada
2022-2023	The Alberta Cellular Therapy and Immune ONcology Initiative (ACTION) Program Steering Committee Member
2021- 2023	The Alberta Cellular Therapy and Immune ONcology Initiative (ACTION) Program Executive Committee Member, Co-Leader of Theme 4 (with Dr. A. Dahli – Hematology).
2021-	Prairie Cancer Research Consortium (PCRC) supported by the Terry Fox Research Institute (TFRI).
2020	Interview of candidates for IMG Clinical Assistants in Medical Oncology, Department of Oncology, University of Calgary, Alberta, Canada
2018/04 -	Alberta Breast Cancer Screening Programs Advisory Committee, member
2018-2022	CHECS – Creating Health Equity in Cancer Screening – Canadian Partnership Against Cancer (CPAC) Project Advisory Committee, member
2018/04 -	Office of Professionalism, Equity and Diversity (OPED), Cummings School of Medicine, collaborator
2018	Department of Oncology Search and Selection Committee, member
2017/08 -	Health Research Ethics Board of Alberta (HREBA), member

2017-2019	Provincial Cancer Care Clinical Ethics Committee, member
2016/07 – 202	22 NRG (NSABP/RTOG/GOG) Oncology –Breast and CNS clinical trials.
2016/07-	Medical Oncology Residency Program, CBD Competency Committee
2016/07-	Medical Oncology Residency Program Committee
2015-2016	Department of Oncology Appointments & Promotions Committee, University of Calgary, Alberta, Canada
2015	Interview of candidates for Head of Oncology Department, Cumming School of Medicine and Alberta Health Services, Calgary, Alberta, Canada
2014-2015	Professionalism Educational Framework Advisory Committee Member, Cumming School of Medicine, Calgary, Alberta, Canada
2014-2015	Interview of candidates for fellowship in Medical Oncology, Department of Oncology, University of Calgary, Alberta, Canada
2013-2014	Resident Group on Professionalism; Professionalism Subcommittee, University of Calgary

Government Agencies

2019/11 Health Sciences Panel of the Ontario Research Fund member, Ministry of Economic

Development, Job Creation and Trade, Canada

2008 Ministry of Public Health of Uruguay.

Consultancy

2017/01 Canadian Brain Tumor Consortium, Research Protocol Review.

2016/11 AMGEN

VIII. RESEARCH SUPPORT

Primary Investigator

Principal Investigator: A phase I-II study of Niacin in patients with newly diagnosed glioblastoma receiving concurrent radiotherapy and temozolomide followed by monthly temozolomide, Investigator Initiated trial. Funded by: CIHR Grant Health Research Foundation July 2019 to June 2020, CAD 5,780,000 (While I am the PI of the clinical trial the PI of the grant is Dr. VW

Yong. Co-Pls: Roldan Urgoiti G, de Robles P, Dunn J, Ling Ch).

2019 Principal Investigator: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled

Study Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Paclitaxel Compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or

Metastatic Triple Negative Breast Cancer.

2019 Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer. 2018 CIHR Cancer Progression & Therapeutics Grant 2017 - CAD 1,243,125 - Mobilizing anti-tumor microglia/macrophages with niacin to improve the prognosis of glioblastoma: Bench to clinical trial and back. Yong, VW, de Robles, P, Dunn J, Kelly J, Roldán Urgoiti G Hotchkiss Brain Institute Translational Grant - CAD 200,000 Mobilizing anti-tumor 2017 microglia/macrophages with niacin to improve the prognosis of glioblastoma: Bench to clinical trial and back. Yong, VW, de Robler, P, Dunn J, Kelly J, Roldán Urgoiti G 2017 Principal Investigator: STELLAR study. Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy 2017 Principal Investigator: NSABP B.37 study. A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer 2017 Principal Investigator: NSABP B.47 study. A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative **HER2-Low Invasive Breast Cancer** 2007 Department of Clinical Neurosciences Scholarship, CAD 20,000. For partial salary support during the Neuro-Oncology Fellowship 2007 Hotchkiss Brain Institute, Denise Lajoie Lake Fellowship for Brain Research (1st recipient), CAD 40,000 for partial salary support and CAD 5,000 for educational expenses. Project: An analysis of image texture and MGMT promoter methylation in glioblastoma using magnetic resonance imaging 2003 Commission of Science Research, Young Investigators' Program Award (University of the Republic, Uruguay, CAD 1,500 (aprox), used for the purchase of expendables during the development of the Masters in Science

To Evaluate The Efficacy And Safety Of Atezolizumab Or Placebo In Combination With

Co-Investigator

Science

2002

2023 Paula de Robles, Cairncross JG< Leckie C, Roldan Urgoiti G, Tsang R. GBM -2022 Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma
HREBA.CC-22-0214 (SIV June 2023)

Program for Biomedical Research (Faculty of Medicine, Uruguay), Manuel Perez Foundation Award, CAD 7,200 (aprox) for partial salary support during the development of the Masters in

Biomechanism in the Association Between Physical Activity, Sedentary Behaviour, Health-Fitness and Breast Cancer Survival: the AMBER Cohort Study. Fiedenreich CM, Courneya KS, Yang L (co-Pls), Benham J, Brenner D, Culos-Reed N, Kopciuk K, McNeely M, Morielli A, Roldan Urgoiti G, WVallance J (co-ls), Matthews C (collaborator) CAD 1,935,000. Requested for 5 years. 04/2022-03/2027 (applied CIHR Fall 2021 Grant).

- Alberta Cellular Therapy and Immune Oncology Initiative (ACTION). AB Children's Hospital Foundation CAD 3,176,472 over 5 years; ExCELLerate Canada CFI funding CAD 5,187,685 (not exclusive for Calgary)
- A neuro-oncology exercise program: ACE-NeuroOncology. Culos-Reed N, **Roldan Urgoiti G**, McNeely M, Daun J, Capozzi L, Francis G. Funded by ACF.
- 2021 Prairie Cancer Research Consortium Network Pilot Project. Funded by Terry Fox Research Institute. Chan J, Bonni S, Gallo M, Godbout R, Graham K, Kurz E, Morrissy S, Robbins S, Robson P, **Roldan Urgoiti G**, Senger D, Shemanko C, Wang E, Yang H.
- Investigator Initiated Grant TBCC 2020 CAD 170,805: Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma. De Robles P, Kelly J, Luchman A, Weiss S, Roldan Urgoiti G, Tsang R, Folkman F, Cairncross G.
- 2018 CIHR Operating Grant: Epigenetics Clinical Translation program 2018. CAD 842,000 (Awarded: March 2019 for 4 years) "MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics." Morris D, Bonni S, Joy A, Nixon N, **Roldan Urgoiti G**, Zhang Q.
- Carole May Yates Memorial Endowment for Cancer Research award. CAD 18,900. Evaluation of temozolomide synergy with existing treatments for premenopausal triple negative breast cancer harboring MGMT promoter methylation. Morris D, **Roldan Urgoiti G**, Kornaga E, Chan A, Yang A
- Canadian Cancer Society's annual research grant 2009, CAD 312,282 to be used from 2011 to 2013. This was a grant to develop the clinical trial: Phase I pharmacodynamic and "high content" study of the gamma-secretase inhibitor RO4929097 in patients with recurrent malignant gliomas (MGs) targeting p75NTR to inhibit brain tumour initiating cells (BTICs) and recurrent invasive gliomas. PI: Peter Forsyth. This clinical trial was closed because the pharmaceutical company discontinued RO4929097

IX. INVITED ADDRESSES / PRESENTATIONS

i. Invited Addresses

- 2024/04 Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 24/2021.
 University of Calgary and University of Alberta. Oral presentation on General Practitioner in Oncology Focused Training Program and Hospitalist service in Arthur Child CCC.
- 2024/04 Professionalism Workshop in AIMG Externship Orientation, Alberta International Medical Graduates, Calgary, AB
- 2024/01 Speaker Medical Oncology Resident Retreat A day in the life of a Medical Oncologist, Kananaskis, Alberta.
- 2023/06 Professionalism Workshop in AIMG Fellowship Orientation, Alberta International Medical Graduates, Calgary, AB

2022/04	Panelist ACTION Research Retreat May 19. "Challenges and Opportunities for clinical translation in Canada".
	Professionalism Workshop in AIMG Externship Orientation, Alberta International Medical Graduates, Calgary, AB
2022/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 24/2021. University of Calgary and University of Alberta. Oral presentation on General Practitioner in Oncology Focused Training Program.
2022/01	Neuro Oncology Journal Club Jan 19/2022 NiacinCNS2020 clinical trial presentation
2021/05	Professionalism Workshop in AIMG Externship Orientation, May 17/2021, Alberta International Medical Graduates, Calgary, AB
2021/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 24/2021. University of Calgary and University of Alberta. Oral presentation on General Practitioner in Oncology Focused Training Program.
2020/06	Professionalism Workshop in AIMG Externship Orientation, June 17/2020, Alberta International Medical Graduates, Calgary, AB
2020/05	Professionalism Workshop in the Orientation for Internationally Trained Physicians starting Fellowships, PGME, Cumming School of Medicine, Calgary, AB
2019/10	Community Oncology Tumour Team Update Meeting: Hormonal Receptor Positive Breast Cancer treatment and General Practitioner in Oncology Program, October 18 and 19/2019, Edmonton, AB
2019/09	Speaker at Provincial CNS Tumor Site Meeting: Clinical trials at TBCC; Sep 27/2019, Edmonton, AB
2019/07	Professionalism Workshop in the Orientation for Internationally Trained Physicians, July 2/2019, PGME, Cumming School of Medicine, Calgary, AB
2019/04	Professionalism Workshop in AIMG Externship Orientation, April 22/2019, Alberta International Medical Graduates, Calgary, AB
2019/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 13/2019. University of Calgary and University of Alberta. Oral presentation on General Practitioner in Oncology Focused Training Program.
2019/01	Speaker Medical Oncology Resident Retreat – Academic vs Community Oncology, Jan 26, 2019, Kananaskis, Alberta.
2018/10	Speaker at the Arnie Charbonneau Cancer Institute External Advisory Board Meeting, Oct 23, 2018, Calgary, Alberta.
2018/10	Breast Cancer Update – 2018 Provincial Community Oncology Meeting Oct 12-13, 2018, Edmonton, Alberta.
2018/05	Medical Professionalism Workshop – International Institute for Medical Education Leadership. Cumming School of Medicine, Office of Professionalism, Equity and Diversity. May 28-June 8, 2018

2018/04	Family Physicians & Cancer Control: Strengthening Linkages Workshop; April 14/2018. University of Calgary and University of Alberta. Oral presentation on Cultural Differences in Breast health
2018/03	Breast Cancer Provincial Meeting – Role of Molecular Signature Tests in Axilla Positive Breast Cancer. March 9/2018, Edmonton, AB
2016/05	Carpe Diem my journey towards academic Medical Oncology and the path ahead. Dept. of Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, AB
2016/05	Utilization of the 21-gene assay for breast cancer treatment decision-making in Alberta – Dept. of Oncology Research Day, University of Calgary, AB
2016/02	Locoregional treatment versus no treatment of the primary tumor in metastatic breast cancer: an open label randomized controlled trial – Medical Oncology Journal Club, Department of Oncology, Calgary, Alberta
2014/11	Fast track from bench to bedside in Melanoma – Medical Oncology Journal Club, Department of Oncology, Calgary, Alberta
2014/08	Multidisciplinary management of most frequent primary brain tumours. 5 th Winter Oncology Conference. August 15-16 2014, Montevideo, Uruguay
2013/12	News from SNO 2013 - December 6/1013, Moffitt Cancer Centre, Tampa, Florida, US
2012/11	Non metastatic neurologic complications of cancer patients. 12th Uruguayan Oncology Conference, 1st International Course in Neuro-Oncology. Nov 21-24 2012, Montevideo, Uruguay
2012/11	Systemic treatment of brain metastases. 12th Uruguayan Oncology Conference, 1st International Course in Neuro-Oncology. Nov 21-24 2012, Montevideo, Uruguay
2010/11	Current state and future management of the treatment of gliomas. XI Uruguayan National Oncology Meeting. Nov 25-27 2012, Montevideo, Uruguay
2010/11	Controversies and perspectives in the management of gliomas. IV Uruguayan Neurology Congress. Nov 29- Dec 3 2010, Punta del Este, Uruguay
2010/11	Molecular targets in Neuro-Oncology. Theory vs evidence. IV Uruguayan Neurology Congress. Nov 29- Dec 3 2010, Punta del Este, Uruguay
2007/05	Neuro-Oncology: From bench to bedside and back again. Juravinski Cancer Centre Regional Oncology Rounds, Hamilton, Ontario
2007/01	Current strategies and future perspectives in gliomas. Holly Cross Cancer Centre Oncology Grand Rounds, University of Alberta, Edmonton, Alberta

ii. Abstracts - Oral Presentations

Daun JT, McDonough MH, **Roldan-Urgoiti G**, Bansal M, Capozzi LC, Easaw JC, McNeely ML, Francis GJ, Culos-Reed SN. (10/2024). Healthcare Providers' and Exercise Specialists' Perspectives of Exercise Integrated into Neuro-Oncology Care. Society for Integrative Oncology (SIO) Conference. Costa Mesa, CA, USA. Oral Presentation.

- Daun JT, Capozzi LC, McLaughlin E, Dhruva T, **Roldan-Urgoiti G**, McDonough MH, Easaw JC, McNeely ML, Francis GJ, Williamson T, Danyluk J, Ospina PA, Lesiuk C, Culos-Reed SN. (06/2024). Tailoring Exercise Prescription to Support Individuals Living with and Beyond Brain Cancer. Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Lille, France. Poster Presentation.
- Daun JT, Dow M, Stuckert N, Dhruva T, Bansal M, Capozzi LC, McDonough MH, **Roldan-Urgoiti G**, Easaw JC, McNeely ML, Francis GJ, Williamson T, Culos-Reed SN. (06/2024). Empowering Neuro-Oncology Patients as Partners in Exercise Oncology Programming. Canadian Association of Psychosocial Oncology (CAPO) Conference. Calgary, AB, Canada. Oral Presentation.
- Daun JT, Capozzi LC, McDonough MH, **Roldan-Urgoiti G**, Easaw JC, McNeely ML, Francis GJ, Dhruva, T, Williamson T, Danyluk J, McLaughlin E, Ospina PA, Gobeil E, Sellar C, Lesiuk C, Culos-Reed SN. (20-22/06/2023). The Feasibility of a Tailored Neuro-Oncology Exercise Program: Work to Date. Canadian Association of Psychosocial Oncology (CAPO) Conference. Montreal, QC, Canada. Oral Presentation.
- Daun JT, Capozzi LC, McDonough MH, **Roldan-Urgoiti G**, Easaw J, McNeely ML, Francis GJ, Williamson T, Danyluk J, McLaughlin E, Ospina PA, Eisele M, Gobeil E, Sellar C, Lesiuk C, Culos-Reed SN. (29/08/2022-1/9/2022). Capturing the Neuro-Oncology Patient Experience in Exercise Programming. Canadian Association of Psychosocial Oncology (CAPO)/International Psycho-Oncology Society (IPOS) World Congress. Toronto, Canada.Oral Presentation. Journal of Psychosocial Oncology Research and Practice, 4:S1
- Daun J, Capozzi L, **Roldan-Urgoiti G**, McDonough M, Easaw J, McNeely M, Francis G, de Guzman Wilding M, Radke L, Lesiuk C, Culos-Reed, S. ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients. Canadian Association of Psychosocial Oncology Annual Meeting. June 8-10, 2021 (virtual)
- 2019/09 Wang MH, Doll C, Ghosh S, Fairchild A, Usmani N, Tankel K, Nijjar T, Severin D, Mulder K, Roldan-Urgoiti G, Mathen P, and Joseph K. External Validation of 7th and 8th Editions of the AJCC TNM Staging Classification System for Anal Canal Cancer: A Multi-Institutional Quality Assurance Study. Radiother Oncol 2019; 139(Suppl 1), Abstr 139.
- Wang MH, Doll C, Ghosh S, Fairchild A, Usmani N, Tankel K, Nijjar T, Severin D, Mulder K, Roldan-Urgoiti G, Mathen P, and Joseph K. Comparison of 7th and 8th Editions of the AJCC TNM Staging Classification System for Anal Canal Cancer: A Multi-Institutional External Validation Study. Int J Radiat Oncol Biol Phys 2019; 105(Suppl 1), Abstr 2398.
- Jiang WN, Chan AM, **Roldán Urgoiti G**, Kornaga E, Mather P, Yeung R, Konno M, Lee S, Box A, Kobel M, Josef KJ, Doll C. The Prognostic Impact of PD-L1 and CD8 Expression in Anal Cancer Patients Treated with Chemoradiotherapy; ASTRO October 21 24, 2018 in San Antonio, Texas.
- 2018/04 Ahmed O, Cheung W, **Roldán Urgoiti G**. Population based analysis of male patients with breast cancer. Canadian Medical Oncology Society Meeting, April 27/2018, Toronto, Ontario.

- 2017/03 **Roldán Urgoiti G**, Ibnshamsah F, Yang H, Lupichuk S. Impact of routine subspecialty pathology review on the care of women age </= 65 years with lymph node negative breast cancer. Provincial Breast Tumour Team Meeting. March 17, 2017. Calgary, AB.
- Mahen P, Mcintyre, J., **Roldán Urgoiti G**, Box, A., Koebell, M., Chan, A., Joseph, K., Doll, CM. Mutational Spectrum Of Anal Cancers From Patients Treated With Radical Chemoradiotherapy. Oral Presentation: ASTRO 58TH Annual Scientific Meeting. Boston, Massachusetts. September 27, 2016.
- 2016/09 Mathen, P., Mcintyre, J., **Roldan-Urgoiti, G.**, Box, A., Koebell, M., Chan, A., Joseph, K., Doll CM. Mutational Spectrum Of Anal Cancers From Patients Treated With Radical Chemoradiotherapy. Oral Presentation: CARO 30th Annual Scientific Meeting. Banff, Alberta, Canada. September 15 2016
- 2016/04 **Roldán Urgoiti G**, Ho C, Leugner D, Easaw J, Lim G. Risk of VTE in Glioblastoma Patients Treated with Concurrent Chemoradiotherapy. CAMO 2016, April 28 2016, Toronto, ON
- 2016/04 **Roldán Urgoiti G**, Ibnshamsah F, Yang H, Lupichuk S. Impact of routine subspecialty pathology review on the care of women age </= 65 years with lymph node negative breast cancer: a practice review. CAMO 2016, April 28 2016, Toronto, ON 2nd place award.
- de Groot J, Kalu F, Viceer N, **Roldán Urgoiti G**, Brownell K. Developing a professionalism education framework to support an appreciative culture of professionalism. Abstract submitted to Academy for Professionalism in Health Care 4th Annual Conference, April 28-30 2016, Philadelphia, PA
- 2014/10 **Roldán Urgoiti G**, Gustafson K, Klimowicz A, Petrillo S, Magliocco A, Doll C. Prognostic Value Of HPV Status And P16 Expression In Patients With Carcinoma Of The Anal Canal. Canadian Society of Internal Medicine. 3rd Award in Basic Research, October/2014, Calgary, Alberta
- 2014/04 **Roldán Urgoiti G.** Prognostic Value Of Hpv Status and P16 Expression In Patients With Carcinoma Of The Anal Canal. Internal Medicine Resident Research Day 2014. April 24/2014, University of Calgary, Alberta.
- 2013/04 **Roldán Urgoiti G.** Population based analysis of patients with ependymoma diagnosed in Alberta from 1975 to 2007. Internal Medicine Resident Research Day 2013, Calgary, Alberta.
- 2011/11 Reiner A, Panageas K, Iwamoto F, Cloughesy t, Aldape K, Rivera A, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, Cairncross JG, **Roldán Urgoiti G**, Wen P, Ligon K, Shiff D, Robins H, Rocque B, Chamberlain M, Mason W, Weaver S, Green R, Kamar F, Abrey L, DeAngelis L, Jhanwar S, Rosenblum M, Lassman A. Recursive Partitioning Analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. 16th Annual Scientific Meeting of the Society for Neuro-Oncology. November 17-20 2011, Anaheim, California, US. Top Abstract plenary session NO-15.
- 2010/ 11 Roldán Urgoiti G, Gustafson K, Klimowicz A, Petrillo S, Chan A, Lees-Miller S, Magliocco A*, Doll C* (*Co-Seniors). The Significance of HPV Status In Patients With Anal Cancer: A Comparative Technical Analysis. ACF Research Conference 2010, November 8-10, Banff, Alberta, Canada.

- 2009/ 11 Doll C, Chan A, **Roldán Urgoiti G**, Diaz R, Klimowicz A, Box A, Magliocco A. The predictive value of p53 and p16 expression in patients with carcinoma of the anal canal. Oral Presentation, Alberta Cancer Research Institute Annual Research Meeting 2009, November 24-26, Banff, Canada.
- 2009/10 Levner I, Drabycz S, **Roldán Urgoiti G**, de Robles P, Mitchell R, Cairncross G. Predicting MGMT gene promoter methylation status of glioblastomas using MRI texture. Society NeuroOncology Annual Meeting 2009, October 22-24, New Orleans, Lousiana.
- Roldán Urgoiti G, Scott J, McIntyre J, Dharmawardene M, de Robles P, Yan E, Parney I, Hussain S, Chan A, Magliocco A, Forsyth P, Cairncross G, Easaw J. Population based study of pseudoprogression after chemoradiotherapy in patients with glioblastoma multiforme. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada.
- Brown R, Zlatescu M, Sijben A, **Roldán Urgoiti G**, de Robles P, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schif D, Cairncross G, Mitchell R. Detecting genetic signatures in oligodendroglioma non-invasively using MR (magnetic resonance). 13th Canadian NeuroOncology Meeting, May 16-18 2008, Banff, Alberta, Canada.
- Roldán Urgoiti G, Sijben A, McIntyre J, de Robles P, Easaw J, Yan E, Forsyth P, Parney I, Magliocco A, Bernsen H, Cairncross G. Toxicity from Chemoradiotherapy in Older Patients with Glioblastoma Multiforme. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada.
- Adler D, de Robles P, **Roldán Urgoiti G**, Drabycz S, Sevick R, Parney I, Yan E, Easaw J, Forsyth P, Magliocco T, McIntyre J, Cairncross G, Mitchell JR. GBM location and MGMT gene promoter methylation are correlated. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada.
- Drabycz S, **Roldán Urgoiti G**, McIntyre J, de Robles P, Adler D, Magliocco A, Cairncross G, Mitchell R. Developing a method for detecting MGMT promoter methylation in glioblastoma multiforme by multiscale texture image analysis based on the Stockwell transform. Educational Programs Research Day 2008, Alberta Cancer Board, Alberta, Canada.
- Forsyth PA, **Roldán Urgoiti G**, George D, Wallace C, Morris DG, Cairncross G, Vallee Matthews M, Markert J, Gillespie GY, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). American Association of Neurological Surgeons (AANS) Meeting 2007, April 14-19, Washington, DC, USA, Platform Presentation.
- 2004/12 Mara C, Rodríguez R, Torres M, **Roldán Urgoiti G**, Ferreira V. Review of the treatment of medulloblastoma and posterior fossa ependymoma. New treatment strategies analysis. 8° National Uruguayan Congress of Oncology & Regional Meeting of Southern Oncologists, December 2-4 2004, Montevideo, Uruguay.
- 2004/12 Sosa A, **Roldán Urgoiti G**, Suarez L. Chemotherapy in patients with hepatic insufficiency. 8° National Uruguayan Congress of Oncology & Regional Meeting of Southern Oncologists, December 2-4 2004, Montevideo, Uruguay.

- Fresco R, L. Delgado, **Roldán Urgoiti G**, A. Sosa, C. Castillo, L. Suárez, K. Lombardo, C. Vargas, V. Blanco, N. Artagaveytia, G. Sabini, I.M.Musé. Pathologic, clinical and biologic characteristics of breast carcinomas in relation to the family history of breast cancer. XII Latinamerican Congress of Mastology, September 17-20 2003, Salvador, Brasil.
- J. Silvera, **Roldán Urgoiti G**, R. Rodríguez. Medulloblastoma. Retrospective analysis of 52 cases (1967-2001). 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay.
- L. Suárez, R. Fresco, **Roldán Urgoiti G**, A. Sosa, C. Castillo. Follow up of patients with rectal cancer in the Clinical Oncology Service Clínicas Hospital. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay.
- 2002/11 Sosa A, **Roldán Urgoiti G**, Suárez L. Meaning of hepatitis B infection in oncologic patients. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay.
- 2000/11 Krygier G, **Roldán Urgoiti G**, Gaggero F, Mañana G, Levin R. Meningeal Carcinomatosis in Solid Tumours. 6º National Uruguayan Congress of Oncology, November 23-25 2000, Montevideo, Uruguay.

iii. Grand Rounds

- 2019/02 Breast cancer tumor group presentation in Oncology Department Grand Rounds, Tom Baker Cancer Centre.
- 2016/05 Carpe Diem... my journey towards academic Medical Oncology and the path ahead. Dept. of Oncology Grand Rounds
- 2015/12 SNO(w) in San Antonio. I love brain tumors... and other incredible true facts. Medical Oncology Noon Rounds, Department of Oncology, Calgary, Alberta
- 2015/10 Drains and Stents: how to get out bile, pus... and other stuff. Medical Oncology Noon Rounds, Department of Oncology, Calgary, Alberta
- 2014/09 Cancer patients in ICU Medical Oncology Noon Rounds, Department of Oncology, Calgary, Alberta
- 2014/08 Multidisciplinary management of most common brain tumors Medical Oncology Noon Rounds, Department of Oncology, Calgary, Alberta
- 2013/03 Use of Methylene Blue in Ifosfamide Encephalopathy. Toxicology Rounds. Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta.
- 2012/11 Granulomatosis with Polyangiitis. Division of Rheumatology Rounds, Health Sciences Centre, Calgary, Alberta.
- The bright light of DNA should not always lead the Path. Clinical-Pathologic Rounds FMC, Department of Medicine, Calgary, Alberta.
- 2012/06 Multiple System Atrophy. Lecons du Mardi a Foothills Hospital, Division of Neurology Rounds, Foothills Medical Centre, Calgary, Alberta.
- 2012/05 Mycobacterium Abscessus. Infectious Diseases Department Rounds, Peter Lougheed Centre, Calgary, Alberta.

2011/12	A geriatrician in the team. Geriatric Oncology. Section of Geriatrics Rounds, Rocky View General Hospital, Calgary, Alberta.
2008/04	Virtual Biopsy of the Brain, Department of Oncology Grand Rounds, Tom Baker Cancer Center, Alberta.
2007/04	From Bench to bedside and back again. Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary, Alberta.
2004/05	Brain metastases of non seminomatous germ cell tumors. Review and presentation of 5 clinical cases, Scientific Meeting of the Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.
2002/10	Actual state of chemoprevention of breast cancer, Scientific Meeting of the Uruguayan Society of Mastology, Montevideo, Uruguay.
2002/07	Clinic-pathologic and therapeutic features of skin lymphomas - Scientific Meeting of the Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.
2002/06	Adjuvant treatment in breast cancer, Scientific Meeting of the Uruguayan Society of Mastology, Montevideo, Uruguay.
2001/08	Durable and complete remission of a metastatic inflammatory breast cancer, Scientific Meeting of the Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.
2001/07	Stromal Gonadal tumours. Three clinical and literature review, Scientific Meeting of the Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.
2001/04	Metastatic endometrial adenocarcinoma: durable and complete response to sequential hormonotherapy, Scientific Meeting of the Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.
2000/08	Primary Central Nervous System Lymphomas. Clinical cases and literature review, Society of Medical and Paediatric Oncology of Uruguay (SOMPU), Montevideo, Uruguay.

iv.

X. PUBLICATIONS

i. Peer Reviewed Manuscripts

- 1. Daun JT, Capozzi LC, Dhruva T, **Roldan Urgoiti G**, McDonough MH, McLaughlin E, Bansal M, Brett A, Easaw JC, McNeely ML, Francis GJ, Williamson T, Danyluk J, Ospina PA, Lesiuk C, de Robles P, Leckie C, Culos-Reed SN. (2024). The Feasibility of a Multi-Site, Clinic-Supported, and Tailored Neuro-Oncology Exercise Program. Neuro-Oncology. Submitted April 5, 2024; UNDER REVIEW.
- Capozzi LC, Daun JT, Francis GJ, de Guzman Wilding M, Roldan Urgoiti G, Langelier D, Culos-Reed SN. Feasibility and Implementation of an Oncology Rehabilitation Triage Clinic: Assessing rehabilitation and exercise need and triage pathways within the Alberta Cancer Exercise – Neuro-Oncology Study. *Current Oncology*. 2023; 30(7):6220-6245. https://doi.org/10.3390/curroncol30070461
- 3. Wuerch E, **Roldan Urgoiti G**, Yong VW. The Promise of Niacin in Neurology Neurotherapeutics https://doi.org/10.1007/s13311-023-01376-2 Published Online 21/04/2023.
- 4. Karimi E, Miranda W, Maritan S, Perus L, Rezanejad M, Sorin M, Dankner M, Fallah P, Dose S, Zuo D, Fiset B, Kloosterman D, Ramsay L, Wei Y, Lam S, ALsajjan R, Watsol I, **Roldan Urgoiti G**, Park M,

- Bradsma D, Senger D, Chan J, Akkari L, Petrecca K, Guiot MC, Siegel P, Quail D, Walsh L. Single-cell spatial immune landscapes of primary and metastatic brain tumors". Nature 2023; 614, 555-563.
- Chan A, Roldan Urgoiti G, Lee S, Kornaga E, Mathen P, Yeung R, Enwere E, Box A, Konno M, Koebel M, Kurian J, Doll C. The Prognostic Impact of PD-L1 and CD8 Expression in Anal Cancer Patients Treated with Chemoradiotherapy. Published online 2022 Oct 7. doi: 10.3389/fonc.2022.1000263
 Front Oncol 2022;12:1000263
- 6. Batra A, Nixon N, **Roldan-Urgoiti G**, Hannouf M, Abedin T, Hugh J, King K, Bigras G, Steed T, Lupichuk S. Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer".

 Cancer Treatment and Research Communications 2021 (28); https://doi.org/10.1016/j.ctarc.2021.100401
- 7. Fundytus A, Saad N, Logie N, **Roldan Urgoiti G.** Breast Cancer in Transgender Female to Male Individuals: A Case Report of Androgen Receptor Positive Breast Cancer. The Breast Journal. 2020;26(5): 1007-1012. DOI: 10.1111/tbj.13655.
- 8. **Roldan Urgoiti G**, Gibson C. Cultural Differences in breast health: helping all ethnocultural groups to get screened for cancer. Canadian Family Physician. Online publication. June/2019. https://www.cfp.ca/news/2019/06/13/06-11
- 9. **Roldán Urgoiti G**, Sinnarajah A, Hussain S, Hao D. Paraneoplastic neuropsychiatric syndrome presenting as delirium. BMJ Support Palliat Care. 2016 Jul 28. pii: bmjspcare-2015-001043. doi: 10.1136/bmjspcare2015-001043. [Epub ahead of print]
- Adilman R, Rajmohan Y, Trinkaus M, Chung C, Naseem M, Hammad N, Leonard R, Roldán Urgoiti G, Brooks E, Poonja Z, Simmons C. Social media use amongst oncologists: Results of a national physician survey. J Oncol Pract 2015; JOP.2015.006429
- 11. **Roldán Urgoiti G**, Singh A, Tsang RY, Nordal R, Lim G, Chan J, Starreveld Y, de Robles P, Biagioni B, Hamilton M, Easaw J. Population Based Analysis of Patients with Ependymoma Diagnosed in Alberta from 1975 to 2007. Can J Neurol Sci 2014:41(6):742-7
- Roldán Urgoiti G, Gustafson K, Klimowicz A, Petrillo S, Magliocco A, Doll C. Prognostic Value Of HPV Status And P16 Expression In Patients With Carcinoma Of The Anal Canal. PLOS One 2014; 9(10):e108790
- 13. Panageas K, Reiner A, Iwamoto F, Cloughesy T, Aldape T, Riverab A, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, Cairncross JG, Roldán Urgoiti G, Wen P, Ligon K, Schiff D, Robins I, Rocque B, Chamberlain M, Mason W, Weaver S, Green E, Kamar F, Abrey L, DeAngelis L, Jhanwar S, Rosenblum M, Lassman A. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology 2014; 16(11):1541-6
- 14. Yeung R, McConnell Y, Roxin G, Banerje R, Roldán Urgoiti G, MacLean AR, Buie WD, Mulder KE, Vickers MM, Josep KJ, Doll CM. One versus two cycles of mitomycin C in concurrent chemoradiation for treatment of anal canal carcinoma: an analysis of outcomes and toxicity. Current Oncology 2014; 21(3):e449-456
- 15. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti G, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun;14(6):761-7
- 16. **Roldán Urgoiti G**B, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol 2012; 108 (1):173-7
- 17. Yip S, Butterfield Y, Morozova O, Chittaranjan S,Blough M, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis D, Maslova A, Moore R, Moradian A, Mungall K, Perizzolo M, Qian J, **Roldán Urgoiti G**, Smith E, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall A, Jones S, Morin G, Chan J, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226: 7–16

- 18. Lassman A, Iwamoto F, Cloughesy T, Aldape K, Rivera A, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, Cairncross JG, Roldán Urgoiti G, Wen P, Ligon K, Schiff D, Robins H, Rocque B, Chamberlain M, Mason W, Weaver S, Green R, Kamar F, Abrey L, Deangelis L, Jhanwar S, Rosenblum M, Panageas K. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncol 2011; 13(6):649-59
- 19. **Roldán Urgoiti G**, Chan J, Eliasziw M, Cairncross G, Forsyth P. Leptomeningeal Disease in Oligodendroglial Tumors A Population-Based Study. J Neurooncol 2011; 104 (3):811-5
- 20. Hamilton M, **Roldán Urgoiti G**, Magliocco A, McIntyre JB, Parney I, Easaw J. Determination Of The Methylation Status Of MGMT in Different Regions Within Glioblastoma Multiforme. J Neurooncol 2011; 102(2):255-60
- 21. **Roldán Urgoiti G**, Chan A, Buckner M, Magliocco A, Doll C. The Prognostic Value of Hemoglobin in Patients with Anal Cancer Treated with Chemoradiotherapy. Dis Colon Rectum 2010; 53(8):1127-34.
- 22. Drabycz S, **Roldán Urgoiti G**, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR. An analysis of image texture, tumor location and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010; 49:1398-405.
- 23. Levner I, Drabycz S, **Roldán Urgoiti G**, De Robles P, Cairncross JG, Mitchell R. Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Comput Assist Interv.12(Pt 2):522-30
- 24. Delaney L, Chambers C, **Roldán Urgoiti G**, De Robles P, Cairncross G, Forsyth P, Easaw J. A Feasibility Study to Assess the Integration of a Pharmacist into NeuroOncology Clinic. J Oncol Pharm Pract 2009; 15:79-85
- 25. **Roldán Urgoiti G**, Scott J, McIntyre JB, Dharmawardene M, de Robles P, Magliocco A, Yan E, Parney I, Forsyth P, Cairncross J, Hamilton M, Easaw J. Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM. Can J Neurol Sc 2009; 36: 617-22
- 26. Forsyth PA, **Roldán Urgoiti G**, George D, Wallace C, Morris DG, Cairncross G, Vallee Matthews M, Markert J, Gillespie GY, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). Mol Ther 2008; 16:627-32
- 27. Sijben AE, McIntyre JB, **Roldán Urgoiti G**, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Prick M, Jeuken J, Cairncross JG. Toxicity from Chemoradiotherapy in Older Patients with Glioblastoma Multiforme. J Neuro-Oncol2008; 89: 97-103
- 28. **Roldán Urgoiti G**, George D, Scott JN, Easaw JC, Yan E, Parney I, Cairncross JG, Forsyth P. Leptomeningeal Disease in Oligodendrogliomas: Clinical and Molecular Analysis. Can J Neurol Sci 2008; 35:204-9
- 29. **Roldán Urgoiti G**, Brasher P, Vecil G, Senger D, Rewcastle N, Cairncross G, Forsyth P, Hamilton M. Population-based study of Medulloblastoma: outcomes in Alberta from 1975 to 1996. Can J Neurol Sci 2008; 35:210-5
- 30. Brown R, Zlatescu M, Sijben A, **Roldán Urgoiti G**, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008; 14:2357-62.
- 31. De Robles P, McIntyre JB, Kalra S, **Roldán Urgoiti G**, Cairncross JG, Forsyth P, Magliocco T, Hamilton M, Easaw JC. Methylation Status of MGMT Gene Promoter in Meningiomas. Cancer Genet Cytogenet 2008; 187:25-7
- 32. Tang P, **Roldán Urgoiti G**, Brasher PMA, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA. A Phase II Study of Carboplatin and Chronic High-Dose Tamoxifen in Patients with Recurrent Malignant Glioma. J Neuro-Oncol 2006; 78: 311-6
- 33. **Roldán Urgoiti G**, Delgado L, Muse IM. Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer. Cancer Biol Ther 2006; 5:505-10
- 34. **Roldán Urgoiti G**, Sosa A, Rodríguez R. Anticoagulation in patients with brain tumours. Review. Rev Med Uru 2005; 21:23-9

- 35. **Roldán Urgoiti G**, Rodríguez R, Musé IM. Brain metastases from non seminomatous germ cell tumours. Review and presentation of five clinical cases. Rev Med Uru 2004; 20: 215-20
- 36. Rodríguez R, Aguiar S, Suárez L, Dalla Rosa M, Guerrero L, Lombardo K, **Roldán Urgoiti G**, García N, Aboal C, Luongo A. Brain metastases from solid tumours. Survival analysis of 46 cases. Arch Inst Neurol (Montevideo) 2001; 4: 128-34
- 37. **Roldán Urgoiti G**, Muse IM. Complete prolonged remission of a metastatic inflammatory breast cancer. Arch Med Int Uruguay 2001; 23 (3): 181-5
- 38. Krygier G, **Roldán Urgoiti G**, Gaggero F, Mañana G, Levin R. Meningeal Carcinomatosis in solid tumours. Arch Med Int Uruguay 2000; 22:147-54

ii. Books, chapters peer reviewed

2008

 Roldán Urgoiti G, de Robles P, Cairncross JG. Searching for a new treatment for anaplastic oligodendroglioma. In: New Treatment for Brain Cancer (International Oncology Updates Series). Ed. C Balaňá Quintero. Permanyer, Barcelona, Spain, pp 11-27. Sep 2008.

lii Abstracts - Presented as posters and published peer reviewed.

- Daun JT, Capozzi LC, Dhruva T, **Roldan Urgoiti G**, McDonough MH, McLaughlin E, Easaw JC, McNeely ML, Francis GJ, Williamson T, Danyluk J, Ospina PA, Lesiuk C, de Robles P, Leckie C, Culos-Reed SN. Implementing Tailored Exercise in Neuro-Oncology...What Is Feasible? The 2024 Arnie Charbonneau Research Symposium. Poster Presentation.
- Outcome analysis of patients with recurrent high-grade gliomas treated with oral etoposide (VP16) in Alberta, Canada: a population-based retrospective study <u>Gao Y</u>, Lim C, Ghosh S, Folkman F, Roldan Urgoiti G. (No.: 2023-A-444-EANO) (accepted)
- Empowering Neuro-Oncology Patients as Partners in Exercise Oncology Programming Julia T. Daun, Megan Dow, Nola Stuckert, Tana Dhruva, Mannat Bansal, Lauren C. Capozzi, Meghan H. McDonough, **Gloria Roldan Urgoiti**, Jacob C. Easaw, Margaret L. McNeely, George J. Francis, Tanya Williamson, S. Nicole Culos-Reed abstract Canadian Association of Psychosocial Oncology (CAPO) conference taking place June 6-7 in Calgary, AB.
- Daun JT, Capozzi LC, **Roldan Urgoiti G**, McDonough MH, Easaw JC, McNeely ML, Francis GJ, Williamson T, Danyluk J, McLaughlin M, Ospina PA, de Guzman Wilding M, Radke L, Driga A, Lesiuk C, Culos-Reed SN. ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients Study Protocol. *MedRxiv*. doi: https://doi.org/10.1101/2021.09.08.21263307 Contemporary Clinical Trials-communications
- Daun, J.T., Capozzi, L.C., **Roldan-Urgoiti, G.**, McDonough, M.H., Easaw, J.C., McNeely, M., Francis, G.J., Williamson, T., Danyluk, J., McLaughlin, M., Ospina, P.A., de Guzman Wilding, M., Smith, T., Driga, A., Lesiuk, C., Culos-Reed, S.N. (10/2021). Implementing a Neuro-Oncology Exercise Program Across Alberta. Alberta Cancer Research Conference. Virtual. Poster Presentation.
- 2021/09 Capozzi LC, Daun JT, Francis GJ, de Cuzman Wilding M, Smith T, **Roldan Urgoiti G,**McDonough MH, Culos-Reed SN. September 2021. Neuro-Oncology Rehabilitation Triage

- Clinic Developing a Rehabilitation Decision Making Framework within the Cancer Care. American Congress of Rehabilitation Medicine Conference, Virtual, Poster Presentation.
- 2019/12 Kornaga E, Yang A, Gratton K, Shi Z, Nixon N, **Roldan Urgoiti G**, Morris D. Temozolomide & Vorinostat as a targeted therapy strategy for triple negative breast cancer. Dec 10-14, 2019 San Antonio.Poster #296
- Wang M, Doll C, Ghosh S, Fraichild A, Usmani N, Tankel K, Nijjar T, Severin D, Mulder K, Roldan Urgoiti G, Mathern P, Joseph K. External Validation Of 7th And 8th Editions Of The AJCC TNM Staging Classification System For Anal Canal Cancer: A Multi-Institutional Quality Assurance Study. CARO-CAMRT 2019 Annual Scientific Meeting, 2-5 October 2019, Halifax, Nova Scotia. Poster Presentation.
- Wang M, Doll C, Ghosh S, Fraichild A, Usmani N, Tankel K, Nijjar T, Severin D, Mulder K, Roldan Urgoiti G, Mathern P, Joseph K. Comparison of 7th and 8th Editions of the AJCC TNM Staging Classification System for Anal Canal Cancer: A Multi-Institutional external Validation Study. 2019 Annual Meeting American Society for Radiation Oncology (ASTRO) Sep 15-18, 2019. Chicago, Illinois, USA. Digital Poster Vieweing Q&A Poster # 2398
- Jiang WN, Chan AM, **Roldán Urgoiti G**, Kornaga E, Mather P, Yeung R, Konno M, Lee S, Box A, Kobel M, Josef KJ, Doll C. The Prognostic Impact of PD-L1 and CD8 Expression in Anal Cancer Patients Treated with Chemoradiotherapy; September 12-15, 2018 CARO; Montreal, QC . Poster #39797
- 2018/06 Easaw, J, Btyyong E, Kornaga E, Almuqate A, Sayeed W, Nicolic A, Doha I, **Roldán Urgoiti G**Improved Prognostic Accuracy of Alternative MGMT methylation status cutpoint. A Single
 Institution Experience. . ASCO 2018, June 1-6 2018, Chicago, US . Poster #2052
- 2018/06 Population based analysis of male patients with breast cancer. Ahmed O, Cheung W, **Roldán Urgoiti G**. American Society of Clinical Oncology Annual Meeting 2018, June 1-6, Chicago US. e.18715
- 2017/12 Kornaga E, Gratton K, Shi Q, Yang A, Nixon N, **Roldán Urgoiti G**, Morris D. Temozolomide as a targeted therapy strategy for triple negative breast cancer. San Antonio Breast Cancer Symposium 2017, December 5-9, 2017. Poster #1076
- 2016/09 Peter Mathen, John B. McIntyre, **Roldán Urgoiti G**, Alan Box, Angela Chan, Martin Kobel, Kurian Joseph, Corinne M. Doll. Mutational Spectrum of Anal Cancers from Patients Treated with Radical Chemoradiotherapy. Radiotherapy and Oncology, Vol. 120, S11 Published in issue: September 2016
- 2016/06 **Roldán Urgoiti G**, Ibnshamsah F, Yang H, Lupichuk S. Impact of routine subspecialty pathology review on the care of women age </= 65 years with lymph node negative breast cancer: a practice review. J Clin Oncol 34, 2016 (suppl; abstr e12006)
- 2016/06 **Roldán Urgoiti G**, Smerdon K, Yang H, Bigras G, Hugh J, Tsang R, King K, Lupichuk S. Utilization of the 21-gene assay for breast cancer treatment decision-making in Alberta. J Clin Oncol 34, 2016 (suppl; abstr e12024)
- 2016/04 **Roldán Urgoiti G**, Smerdon K, Yang H, Bigras G, Hugh J, Tsang R, King K, Lupichuk S. Utilization of the 21-gene assay for breast cancer treatment decision-making in Alberta. CAMO 2016, April 28 2016, Toronto, ON. Poster.

- de Groot J, Kalu F, Viceer N, **Roldán Urgoiti G**, Brownell K. Developing a professionalism education framework to support an appreciative culture of professionalism. Annual Health and Medical Education Scholarship Symposium 2016, University of Calgary, AB. Poster
- 2015/11 **Roldán Urgoiti G**, Lawn S, Scott J, Easaw J, Kenchappa R, Taylor J, Paleologos N, Schiff D, Chan J, Forsyth P. Evaluation of p75 expression and patterns of recurrence in patients with malignant gliomas treated with bevacizumab. Society for Neuro-Oncology 20th Annual Scientific Meeting, Nov 19-22 2015, San Antonio, Texas, USA Poster #0292
- 2015/10 **Roldán Urgoiti G**, Sinnarajah A, Hussain S, Hao D. Case report: paraneoplastic neuropsychiatric syndrome presenting as terminal delirium. 26th Annual Palliative Care Education and Research Days, October 26-27, 2015 Edmonton, Alberta. Poster
- 2015/06 **Roldán Urgoiti G**, Lawn S, Scott J, Easaw J, Kenchappa R, Taylor J, Paleologos N, Schiff D, Chan J, Forsyth P. Evaluation of p75 expression and patterns of recurrence in patients with malignant gliomas treated with bevacizumab. J Clin Oncol 33, 2015 (suppl; abstr e13006)
- 2015/05 **Roldán Urgoiti G**, Sinnarajah A, Hussain S, Hao D. Case report: paraneoplastic neuropsychiatric syndrome presenting as terminal delirium. 11th Annual Advanced Learning in Palliative Medicine Conference, Calgary May 28-30 2015. Poster
- 2015/04 **Roldán Urgoiti G**, Lawn S, Scott J, Easaw J, Kenchappa R, Taylor J, Paleologos N, Schiff D, Chan J, Forsyth P. Evaluation of p75 expression and patterns of recurrence in patients with malignant gliomas treated with bevacizumab. CAMO Annual Scientific Meeting April 30/2015, Toronto, Canada. Poster
- 2014/06 Adilman R, Rajmohan Y, Trinkaus M, Chung C, Naseem M, Hammad N, Leonard R, **Roldán Urgoiti G**, Brooks E, Poonja Z, Simmons C. Social media use amongst oncologists: Results of a national physician survey. J Clin Oncol 32, 2014 (suppl; abstr e17519)
- 2013/11 **Roldán Urgoiti G**, Singh A, Tsang RY, Nordal R, Lim G, Chan J, Starreveld Y, de Robles P, Biagioni B, Hamilton M, Easaw J. Population Based Analysis of Patients with Ependymoma Diagnosed in Alberta from 1975 to 2007. Society of Neuro-Oncology Meeting 2013 November 22-14, San Francisco, CA . Poster. Neuro Oncol (2013) 15 (suppl 3):iii34
- Yeung R, McConnell Y, roxin G, Banerjee R, **Roldán Urgoiti G**, MacLean A, Buie D, Mulder K, Vickers M, Kurian J, Doll C. One versus two cycles of mitomycin C in concurrent chemoradiation for treatment of anal canal carcinoma: an analysis of outcomes and toxicity. CARO ACRO Annual Scientific Meeting, Sep 12-15 2012, Ottawa, ON. Poster. Radiotherapy and Oncology Sep 2012; 104 (Suppl 2): S19. Abstract 49.
- 2012/04 **Roldán Urgoiti G**, Craighead P, Walley B, Joy A, Bebb G, Magliocco A, Morris D. Hematological and molecular prognostic factors in patients with localized breast cancer with more than 15 years of follow up. Internal Medicine Research Day 2012, Calgary, Alberta. Poster
- 2011/11 **Roldán Urgoiti G**, McIntyre JB, Easaw J, Magliocco A. Molecular bases of resistance to target therapies in patients with primary and recurrent meningioma. 16th Annual Scientific Meeting of the Society for Neuro-Oncology. November 17-20 2011, Anaheim, California, US. Poster CB-29. euro-Oncology Nov 2011; Suppl 3(13): 16

- Panageas K, Iwamoto F, Cloughesy T, Aldape K, Rivera A, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, Cairncross JG, **Roldán Urgoiti G**, Wen P, Ligon K, Schiff D, Robins H, Rocque B, Chamberlain M, Mason W, Weaver S, green R, Kamar F, Abrey L, DeAngelis L, Jhanwar S, Rosenblum M, Lassman A. Time Trends in treatment of anaplastic oligodendroglial tumors. Poster NO 95. 16th Annual Scientific Meeting of the Society for Neuro-Oncology. November 17-20 2011, Anaheim, California, US. Poster NO-95. Neuro-Oncology Nov 2011; Suppl 3 (13):62.
- 2011/11 Reiner S, Panageas K, Iwamoto F, Cloughesy T, Aldape K, Rivera A, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, Cairncross G, **Roldán Urgoiti G**, Wen P, Ligon K, Schiff D, Robins H, Rocque B, Chamberlain M, Mason W, Weaver S, Green F, Kamar F, Abrey L, DeAngelis L, Jhanwar S, Rosenblum M, Lassman A. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology Nov 2011; Suppl 3(13):43. Abstract NO-15.
- de Robles P, Ramirez L, **Roldán Urgoiti G**, Mitchell R. Differentiating between glioblastoma pseudo-progression and real tumor progression using magnetic resonance imaging texture analysis. 63rd American Academy of Neurology annual meeting, April 9-16 2011, Honolulu, Hawaii, USA. Poster
- 2011/02 **Roldán Urgoiti G**, Gustafson K, Klimowicz A, Petrillo S, Chan A, Lees-Miller S, Magliocco A*, Doll C* (* Co-Seniors). The Significance of HPV Status In Patients With Anal Cancer: A Comparative Technical Analysis. J Clin Oncol Feb 2011; 29 (suppl 4). Abstract 425.
- 2011/01 Doll C, **Roldán Urgoiti G**, Klimowicz A, Gustafson K, Petrillo S, Chan A, Lees-Miller S, Magliocco A. The significance of HPV status in patients with anal cancer: A comparative technical analysis. ASCO 2011 Gastrointestinal Cancers Symposium, January 20-22 2011, San Francisco, California. Poster
- 2010/11 **Roldán Urgoiti G**, Kachra R, McIntyre JB, Magliocco A, Easaw J, Hamilton M. Dual Mgmt Gene Promoter Methylation Status In Recurrent Meningioma. Society of Neuro-Oncology Meeting November 18-21 2010, Montreal, Canada. Poster. J Clin Oncol 2010; 28 (suppl): Abstract e21041.
- 2010/11 **Roldán Urgoiti G**, Kachra R, McIntyre JB, Magliocco A, Easaw J, Hamilton M. Dual Mgmt Gene Promoter Methylation Status In Recurrent Meningioma. Neuro-Oncol Nov 2010; Suppl 4: 64. Abstract OM13.
- 2010/06 **Roldán Urgoiti G**, Klimowicz A, Petrillo S, Yau A, Tang P, Magliocco A. Prognostic value of gli1 expression and its association with hormonal receptors in localized breast cancer. J Clin Oncol 2010; 28 (suppl): Abstract e21041.
- Lassman A, Panageas K, Iwamoto F, DeAngelis L, Rivera A, Aldape K, Cloughesy T, Eichler A, Louis D, Paleologos N, Fisher B, Ashby L, **Roldán Urgoiti G**, Cairncross C, Wen P, Schiff D, Rocque B, Robins H, Chamberlain M, Mason W, Weaver S, Green R, Kamar F, Jhanwar S, Rosenblum M, Abrey L. Oligodendroglioma Study Group. Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncol 2009; 11: 629. Abstract 283.
- 2009/11 Levner I, Drabycz S, **Roldán Urgoiti G**, de Robles P, Mitchell R, Cairncross G. Predicting MGMT gene promoter methylation status of glioblastomas using MRI texture. Neuro-Oncol 2009; 11: 671. Abstract #468.

- Doll C., **Roldán Urgoiti G**., Chan A., Klimowicz A., Petrillo S., Diaz R., Box A., Eliasziw M., Magliocco A. The predictive value of p53 and p16 expression in patients with carcinoma of the anal canal. 23rd Annual Scientific Meeting Canadian Association of Radiation Oncology, Sep 30-Oct 3 2009, Quebec, Canada. Poster #162. Radiother and Oncol 2009; 92 (Suppl 2): 51.
- 2009/10 Hamilton M, Parney I, **Roldán Urgoiti G**, Magliocco A, Steele L, Easaw J. Determination of the methylation status within different regions of glioblastoma multiforme tumors. Society Neuro-Oncology Annual Meeting, October 24-29 2009, New Orleans, Lousiana. Poster # 372. NeuroOncol 2009; 11: 649.
- 2009/09 Levner I, Drabycz S, Cairncross G, **Roldán Urgoiti G**, De Robles P, Mitchell R. Predicting MGMT Methylation Status of Glioblastomas from MRI texture. MICCAI Medical Imaging Computing & Computer Assisted Intervention, Sep 20-24 2009, London, England. Poster
- 2009/06 Lassman A and the Oligodendroglioma Study Group (**Roldán Urgoiti G**, included)
 Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. American Society of Clinical Oncology Annual Meeting, May 29-June 2 2009, Orlando, Florida. Poster #2014. J Clin Oncol 2009; 27 (suppl):15.
- De Robles P, McIntyre J, Kalra S, **Roldán Urgoiti G**, Cairncross G, Forsyth P, Magliocco A, Hamilton M, Easaw J. Methylation Status of MGMT Gene Promoter In Meningiomas. Poster PA25. Society Neuro-Oncology Annual Meeting, Nov 21-23 2008, Las Vegas, Nevada, EEUU. Poster. Neuro-Oncol 2008; 10: 860. Abstract PA-25.
- de Robles P, Adler D, **Roldán Urgoiti G**, Drabycz S, Sevick R, Parney I, Yan E, Easaw J, Forsyth P, Magliocco A, McIntyre J, Cairncross G, Mitchell R. MGMT Gene Promoter Methylation And Tumor Location In Glioblastoma. Society Neuro-Oncology Annual Meeting, Nov 21-23 2008, Las Vegas, Nevada, EEUU. Poster PA-26. Neuro-Oncol 2008; 10: 861.
- 2008/06 **Roldán Urgoiti G**, Sijben A, McIntyre JB, Easaw J, Yan E, Forsyth P, Parney I, Magliocco A, Bernsen H, Cairncross J. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. American Society of Clinical Oncology Annual Meeting, May 30-June 3 2008, Chicago, Illinois, US. Poster #2054. J Clin Oncol May 2008; 26:15.
- 2008/05 Hamilton G, Dean C, Hatcher C, Forsyth P, Parney I, Cairncross G, Joseph J, Curry B, **Roldán Urgoiti G**, Easaw J. Reducing wait times for brain tumor treatment: a collaborative approach.

 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster
- Dharmawardene M, **Roldán Urgoiti G**, Besley B, de Robles P, Easaw J, Scott J, Parney I, Forsyth P, Cairncross G, Yan E. The timing and utility of post-concurrent therapy MRIs in patients with Glioblastoma. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster
- 2008/05 **Roldán Urgoiti G**, Scott J, George D, de Robles P, Parney I, Easaw J, Forsyth P, Cairncross G, Yan E. Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.

 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster
- 2008/05 **Roldán Urgoiti G**, Brasher P, Vecil G, Senger D, Rewcastle B, de Robles P, Cairncross G, Forsyth P, Hamilton M. Population-based study of Medulloblastoma: outcomes in Alberta from 1975 to 1996. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster

- de Robles P, McIntyre J, Kalra S, Cairncross G, Forsyth P, Magliocco A, **Roldán Urgoiti G**, Easaw J. Methylation status of MGMT gene promoter in meningiomas. 13th Canadian NeuroOncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster
- Drabycz S, **Roldán Urgoiti G**, McIntyre J, de Robles P, Adler D, Magliocco A, Cairncross G, Mitchell R. Developing a method for detecting MGMT promoter methylation in glioblastoma multiforme by multiscale texture image analysis based on the Stockwell transform. 13th Canadian Neuro-Oncology Meeting, May 16-18 2008, Banff, Alberta, Canada. Poster
- 2007/11 **Roldán Urgoiti G**, George D, Scott J, Easaw J, Yan E, Parney I, Cairncross G, Forsyth P. Leptomeningeal Disease in Oligodendrogliomas: Clinical and Molecular Analysis. Poster PA-35. Society of Neuro-Oncology Meeting, Nov 15-18 2007, Dallas, Texas, EEUU. Poster
- 2007/11 Bourque S, McIntyre J, Cairncross G, Forsyth P, Magliocco A, **Roldán Urgoiti G**, de Robles P, Yan E, Parney I, Hussain S, Chan A, Abdul-Karim B, Fulton D, Murtha A, Roa W, Lim S, Easaw J. Glioblastoma in Alberta: A Retrospective Analysis. Alberta Cancerboard Research Meeting, Nov 6-8 2007, Banff, Alberta. Poster
- 2007/06 **Roldán Urgoiti G**, George D, Scott J, Easaw J, Yan E, Parney I, Cairncross G, Forsyth P. Leptomeningeal Disease in Oligodendrogliomas: Clinical and Molecular Analysis. Poster and Poster Discussion 2019. American Society of Clinical Oncology Meeting, June 1-5 2007, Chicago, Illinois. Poster. J Clin Oncol 2007; 25: 18. Abstract 2019.
- Forsyth PA, **Roldán Urgoiti G**, George D, Wallace C, Morris DG, Cairncross G, Vallee Matthews M, Markert J, Gillespie GY, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). American Association of Neurological Surgeons (AANS) Meeting, Apr 2007. Published online: http://www.aans.org/Media/Article.aspx?ArticleId=40719. Abstract 40719
- Forsyth PA, **Roldán Urgoiti G**, George D, Wallace C, Morris DG, Cairncross G, Vallee Matthews M, Markert J, Gillespie GY, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). Society of Neuro-Oncology Meeting, Nov 16-19 2006, Orlando, Florida. Poster TA-18.
- Forsyth PA, **Roldán Urgoiti G**, George D, Wallace C, Morris DG, Cairncross G, Vallee Matthews M, Markert J, Gillespie GY, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). American Society of Clinical Oncology Meeting, June 2-6 2006, Atlanta, Georgia. Poster #1563
- Della Valle A, **Roldán Urgoiti G**, Suárez L, Rodríguez R, Quarneti A. Neoadjuvant treatment in rectal cancer. 8° National Uruguayan Congress of Oncology & Regional Meeting of Southern Oncologists, December 2-4 2004, Montevideo, Uruguay. Poster
- 2004/12 **Roldán Urgoiti G**, Arén O, Varangot M, Levin R, Delgado L, Viola A, Vázquez A, Musé I. Testicular seminomatous tumours. Unusual presentations and clinical evolution. 8° National Uruguayan Congress of Oncology & Regional Meeting of Southern Oncologists, December 2-4 2004, Montevideo, Uruguay. Poster

- 2004/09 Rodríguez R, **Roldán Urgoiti G**, Sosa A, Mañana G, Rodríguez A, Panuncio A. Primary Lung Melanoma. Clinic-pathologic considerations about a clinical case. 2nd. Uruguayan Congress of Neurology, Sep 8-11 2004, Colonia, Uruguay. Poster
- 2004/09 Rodríguez A, Mañana G, Panuncio A, Rodríguez R, **Roldán Urgoiti G**, Sosa A. Two unusual cases of brain metastases of lung primary malign melanoma. 2nd Uruguayan Congress of Neurology, Sep 8-11 2004, Colonia, Uruguay. Poster
- 2004/09 Rodríguez R, **Roldán Urgoiti G**, Mañana G. Oligodendrogliomas. Analysis of 77 cases treated in the Neuro-Oncology Unit from 1970 to 2004. 2° Uruguayan Congress of Neurology, Sep 8-11 2004, Colonia, Uruguay. Poster
- Sosa A, **Roldán Urgoiti G**, Cataldi S, Musé IM. Retrospective analysis of 9 patients with non seminomatous germ cell tumours of the testis refractive to cisplatin based chemotherapy. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay. Poster
- 2002/11 Cataldi S, **Roldán Urgoiti G**, Vázquez A, Cuello M, Terzieff V, Rodriguez R. Chordomas, literature review and presentation of eight clinical cases. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay. Poster
- Delgado L, **Roldán Urgoiti G**, Fresco R, Sosa A, Castillo C, Suárez L, Lombardo K, Vargas C, Blanco V, Artagaveytia N, Sabini G, Musé IM. Clinical-pathologic features of breast carcinomas in relation with the family history of breast cancer. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay. Poster
- 2002/11 Rodríguez R, Silvera J, **Roldán Urgoiti G**. Treatment of primary brain tumours with carboplatinetoposide. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay. Poster
- 2002/11 Rodríguez R, Lombardo K, **Roldán Urgoiti G**, Silvera J, Lagomarsino R. Hemispheric Glioblastoma Multiforme. Survival analysis of 65 cases. 7º National Uruguayan Congress of Oncology, November 21-23 2002, Montevideo, Uruguay. Poster
- 2000/11 **Roldán Urgoiti G**, Suárez L, Rodríguez R, Quarnetti A, Aguiar S, Gordon-Firing S. Ependymal Tumours. 6º Uruguayan Congress of Oncology, November 23-25 2000, Montevideo, Uruguay. Poster
- 2000/11 Delgado L, Vargas C, Lombardo K, Suárez L, Fresco R, **Roldán Urgoiti G**, Blanco V, Artagaveytia N, Sabini G, Musé I. Clinical, pathologic and biologic features of breast cancers in relation to family history of breast cancer. 6º National Uruguayan Congress of Oncology, November 23-25 2000, Montevideo, Uruguay. Poster
- 2000/11 Fresco R, **Roldán Urgoiti G**, Servente L, Sabini G, Viola A, Musé IM. Non seminomatous germ cell tumours of the testis. 6º National Uruguayan Congress of Oncology, Nov 23-25 2000, Montevideo, Uruguay. Poster

v. Projects in progress

06/2023 MGMT Promoter Methylation Status in Glioblastoma: A Single Institutional Experience Erik Nohr, Abdullah Almuqate, Wajid Sayeed, Eugene Batuyong, Elizabeth Kornaga, Ana Nikolic, Madison Gray, Jay Easaw, Gloria Roldan-Urgoiti, Doha Itani

PROTECT Pan Canadian review of the treatment of oligodendroglioma with PCV vs TMZ (in collaboration with The Ottawa Hospital Cancer Centre) – already submitted AB data.

- 03/2021- A phase I-II study of Niacin in patients with newly diagnosed Glioblastoma receiving concurrent radiotherapy and Temozolomide followed by monthly Temozolomide. Sep 2023 completed Phase 1
- 03/2021- A Randomized Phase 2 Study of Temozolomide monotherapy or in combination with Olaparib in patients with 06-Methylguanine-DNA Methyltransferase (MGMT) methylated Triple Negative Breast Cancer (TNBC). Health Canada Approved. In Launch.

XI. PATENTS AND COPYRIGHTS

None.